BNTX

BioNTech SE (BNTX)

Last Price$122.90.6%
Market Cap$29.5B
LTM Gross Profit
$2,781.1M
YoY Growth
-39.4%
3Y CAGR
-39.9%
5Y CAGR
N/A
Stock quality & Intrinsic value
6/10
33.5% undervalued

BioNTech SE Gross Profit

Annual
Quarterly
LTM
Crunching data... Almost there!
Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Gross Profit
$0.0
($37.5M)
($34.4M)
($151.4M)
($253.5M)
$17.9B
$13.5B
$3,481.2M
BNTX
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for BNTX and see if it's the right time to invest.
Dive in

BioNTech SE (BNTX) Gross Profit comparison analysis

Crunching data... Almost there!

BNTX key stats

USD
EUR
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Crunching data... Almost there!

Discover more Stock Ideas

Loved by
investors
worldwide
10K+
Investors use our platform
#1
Top value investing hub with all necessary tools
1K+
Experienced investors in our community
4.9
Average rating across all rating platforms

FAQ

1) What is BioNTech SE's Gross Profit?

As of today, BioNTech SE's last 12-month Gross Profit is $2,781.1M, based on the financial report for Sep 30, 2024 (Q3 2024).

2) What is BioNTech SE's Gross Profit growth rate?

Over the last year, BioNTech SE's Gross Profit growth was (39.4%). The average annual Gross Profit growth rates for BioNTech SE have been 13.4% over the past three years, N/A over the past five years.

4) How does BioNTech SE's Gross Profit growth rate compare to its peers?

Over the last year, BioNTech SE's Gross Profit growth was (39.4%), which is lower than peer median growth of 5.5%. The list of peers includes NVO, REGN, VRTX, INCY, MRNA, GMAB, BGNE, UTHR, ARGX, ALNY etc.